RyboDyn Inc.

- 10/01/2025
- Pre-Seed
- $4,000,000
RyboDyn, Inc. is targeting the dark proteome to make new immunotherapies. We are unlocking and validating previously undiscovered, disease-specific targets that will impact the treatment of cancer and autoimmune diseases by driving a new wave of targeted therapeutics. Our "targets-to-assets" therapeutics development program is supported by a scalable, in-house platform for lead discovery and optimization. We aim to deliver first-in-class assets that recognize these targets for treating solid tumors and diseases lacking effective treatment options.
- Industry Biotechnology Research
- Website https://www.rybodyn.com/
- LinkedIn https://www.linkedin.com/company/rybodyn/
Related People
Imad Ajjawi, PhD, MBACo Founder

Biotechnology entrepreneur passionate about revolutionizing the biotech industry. Founded Denovium, an AI biotech company for protein discovery and design. Acquired by Absci. IPO less than a year later at a $1.5B pre-money valuation. Secured >$100M funds via strategic partnerships, M&A and VCs. Authored >25 patents and peer-reviewed manuscripts (see Google Scholar). Featured in WIRED, Forbes, Bloomberg, NPR, and other media outlets.